A groundbreaking team of scientists and engineers, previously working under a high-profile Big Tech initiative in London, is on the verge of launching a new biotechnology venture with plans to secure up to $700 million in funding. The start-up, named Emulate, aims to revolutionize drug discovery and medical research by developing advanced human organ models that replicate biological functions with unprecedented accuracy. Their innovative approach could accelerate the development of treatments for complex diseases while reducing reliance on traditional animal testing. Industry observers are watching closely as the project transitions from corporate lab to independent enterprise, potentially reshaping the future of precision medicine.
Researchers leaving Big Tech group’s London lab close to raising $700mn for new start-up Emulate
